Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Exicure stock

Own Exicure stock in just a few minutes.


Fact checked

Exicure, Inc is a biotechnology business based in the US. Exicure shares (XCUR) are listed on the NASDAQ and all prices are listed in US Dollars. Exicure employs 57 staff and has a trailing 12-month revenue of around USD$16.8 million.

How to buy shares in Exicure

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Exicure. Find the stock by name or ticker symbol: XCUR. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Exicure reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. Weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Exicure, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Exicure. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Exicure share price

Use our graph to track the performance of XCUR stocks over time.

Exicure shares at a glance

Information last updated 2020-11-25.
52-week range USD$0.9573 - USD$3.84
50-day moving average USD$1.6686
200-day moving average USD$2.1796
Wall St. target price USD$11
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-0.471

Buy Exicure shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee
Stocks, Mutual funds, ETFs, Forex
$20 per year
Get a personal advisor when you open an account with at least $50,000.
Stocks, Options, ETFs, Cryptocurrency
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Sofi Invest
Stocks, ETFs, Cryptocurrency
A free way to invest in stocks, ETFs and crypto.
Interactive Brokers
Stocks, Bonds, Options, Mutual funds, Index funds, ETFs, Futures, Cash
$0 + $0.65/contract, $1 minimum
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
TD Ameritrade
or $25 broker-assisted
$0 + $0.65/contract,
or $25 broker-assisted
TD Ameritrade features $0 commission for online stock, but watch out for high short-term ETF and broker-assisted trading fees.

Compare up to 4 providers

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Exicure stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Exicure financials

Revenue TTM USD$16.8 million
Gross profit TTM USD$-18,044,000
Return on assets TTM -15.59%
Return on equity TTM -31.74%
Profit margin -130.87%
Book value $0.842
Market capitalisation USD$122.1 million

TTM: trailing 12 months

Shorting Exicure shares

There are currently 962,414 Exicure shares held short by investors – that's known as Exicure's "short interest". This figure is 3.3% down from 995,440 last month.

There are a few different ways that this level of interest in shorting Exicure shares can be evaluated.

Exicure's "short interest ratio" (SIR)

Exicure's "short interest ratio" (SIR) is the quantity of Exicure shares currently shorted divided by the average quantity of Exicure shares traded daily (recently around 149443.16770186). Exicure's SIR currently stands at 6.44. In other words for every 100,000 Exicure shares traded daily on the market, roughly 6440 shares are currently held short.

However Exicure's short interest can also be evaluated against the total number of Exicure shares, or, against the total number of tradable Exicure shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Exicure's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Exicure shares in existence, roughly 10 shares are currently held short) or 0.0145% of the tradable shares (for every 100,000 tradable Exicure shares, roughly 15 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Exicure.

Find out more about how you can short Exicure stock.

Exicure share dividends

We're not expecting Exicure to pay a dividend over the next 12 months.

Exicure share price volatility

Over the last 12 months, Exicure's shares have ranged in value from as little as $0.9573 up to $3.84. A popular way to gauge a stock's volatility is its "beta".

XCUR.US volatility(beta: 1.5)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Exicure's is 1.498. This would suggest that Exicure's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Exicure overview

Exicure, Inc., a clinical-stage biotechnology company, develops therapeutics for neurology, immuno-oncology, inflammatory diseases, and genetic disorders based on its proprietary spherical nucleic acid (SNA) technology. Its drug candidate includes AST-008 that is in a Phase 1b/2 clinical trials in patients with advanced solid tumors. The company is also developing XCUR-FXN, an SNA?based therapeutic candidate that is in preclinical trials for the treatment of Friedreich's ataxia; and XCUR17, an SNA that targets the messenger RNA (mRNA) encoding interleukin 17 receptor alpha. It has a collaboration, option, and license agreement with Allergan Pharmaceuticals International Limited to develop SNA-based treatments for hair loss disorders; and license and development agreement with DERMELIX, LLC to research, develop, and commercialize its technology for the treatment of netherton syndrome. The company was founded in 2011 and is based in Chicago, Illinois.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site